Statistics show 10 percent of the people in the UK are affected with prediabetes. Within 10 years period, 5 to 10 percent of the people with prediabetes condition will progress into diabetes condition. Prediabetes condition is easy to cure with diet and exercise but it is hard to cure a diabetes condition. A study done by researchers from Imperial College, London UK shows prevention of prediabetes condition (also known as "borderline diabetes") with the usage of Liraglutide diabetes drug along with diet and exercise program. Liraglutide diabetes drug increase appetite suppressing hormones in the gut. The researchers studied 2,254 obese and prediabetes individuals worldwide and studied the effects of self-administered injections of Liraglutide along with diet and exercise program compared with only diet and exercise program to prevent progression of diabetes.
After 3 years, the study results show 80 percent reduction in the development of diabetes in prediabetes patients using Liraglutide compared with Placebo. It also found that 60 percent of the prediabetes patients using Liraglutide have successfully reversed their prediabetes condition to normal blood sugar levels. Patients under Liraglutide took three times longer time in moving into diabetes condition from prediabetes condition compared to patients under placebo medication. Usage of Liraglutide diabetes drug was associated with better-sustained weight loss (7 percent) after three years compared with placebo (2 percent).
Liraglutide is diabetes drug to manage type ii diabetes (T2D) condition. But the success of Liraglutide in preventing type 2 diabetes (T2D) condition is very interesting. Co-author of the study says Liraglutide drug mimics the action of GLP-1, a hormone produced naturally in our body to suppress and regulate our appetite. A Novo Nordisk funded project was co-authored by Le Roux, Department of Medicine, Imperial College, London UK and the study findings were published in the Lancet.
A study done by researchers shows the development of dementia risk later in life in those middle age people, aged between 45 and 64 having heart disease risks. The investigators studied the associations between vascular risk factors and dementia development over a 25 years period. Investigators found high dementia risk in old, less educated and black people with hypertension, smoking and diabetes and those carried APOE e4.
The researchers say the current study is an observational study and they did not study if treating risk factors reduces dementia risk later in life. Participants of the study are Gottesman RF, Albert M and Coker L and the study findings were presented at the 2017 International Stroke Conference in Houston.
Recent studies show Jardiance diabetes drug has the power to reduce blood sugar or glucose levels and cardiovascular problems. Australian doctors got authorization to prescribe Jardiance diabetes drug to treat cardiovascular events in type 2 diabetes (T2D) patients. The Therapeutic Goods Administration, a regulatory body for therapeutic goods, Department of Health, Australia listed Jardiance drug under the medicines to treat cardiovascular diseases in type 2 diabetes (T2D) patients. Jardiance is a sodium glucose co-transporter-2 inhibitor (SGLT2) drug. This drug prevents excess glucose or sugar levels in the blood by blocking reabsorption of sugar or glucose in the kidney from urine.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.